论文部分内容阅读
非酒精脂肪性肝病(NAFLD)患者的主要死因为动脉硬化性血管病变和糖尿病,而肝病相关残疾和死亡的情况几乎仅见于非酒精性脂肪性肝炎(NASH)患者。NAFLD的治疗对策可分为基本治疗、药物辅助治疗和终末期肝病治疗。其中,基本治疗就是防治原发基础疾病及其相关危险因素,包括饮食调整、增加运动和行为疗法;药物辅助治疗可以防治肝内炎症、坏死和纤维化;发展到终末期肝病(如脂肪性肝硬化、肝癌和肝功能衰竭)时,只能做肝移植。但是,肝移植也要在代谢紊乱控制良好的基础上才能取得较好的疗效,才不会出现移植肝复发。
The leading cause of death in patients with non-alcoholic fatty liver disease (NAFLD) is atherosclerotic vascular disease and diabetes, and liver-related disability and death are found only in patients with non-alcoholic steatohepatitis (NASH). The treatment of NAFLD can be divided into basic treatment, drug-assisted therapy and end-stage liver disease treatment. Among them, the basic treatment is the prevention and treatment of primary underlying diseases and related risk factors, including dietary adjustments, increased exercise and behavioral therapy; drug adjuvant therapy can prevent intrahepatic inflammation, necrosis and fibrosis; development to end-stage liver disease (such as fatty liver Sclerosis, liver cancer and liver failure), can only do liver transplantation. However, liver transplantation should also be based on the control of metabolic disorders in order to achieve better efficacy, it will not appear graft recurrence.